Pipeline

Pipeline Overview

We are assembling a robust portfolio of allogeneic iPSC derived NK, γδ and αβ T cell therapy product candidates for cancer and autoimmune diseases. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses. Enhancements in this platform have led to the generation of cells with pan-resistance to host T cell, NK, and antibody (ADCC/ADCP/Complement) mediated rejection to potentially optimize and increase the probability of success of our programs across hematology, oncology and autoimmune diseases.
Product iPSC
PLATFORM
Targets Indications Research Ind-enabling Clinical P1 P2 P3 Collaborator
Autoimmune Diseases
CNTY-101
iNK
CD19
SLE and LN Additional Indications

CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.

CNTY-101 is currently being evaluated in the Phase 1 CALiPSO-1 trial (NCT06255028) for moderate to severe systemic lupus erythematosus and lupus nephritis.

CNTY-108
iNK/γδ ιΤ
CD19
Autoimmune Diseases

CNTY-108 is an iPSC-derived CD19 targeting allogeneic iNK or γδ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-108’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-108 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.

CLDE-308
αβ ιΤ
CD19
Autoimmune Diseases

CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.

CLDE-361
αβ ιΤ
BCMA
Myasthenia Gravis

CLDE-361 is a BCMA targeting CD4+ and CD8+ αβ iT product candidate for myasthenia gravis. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-361’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-361 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.

Hematologic and Solid Tumors
CNTY-101
iNK
CD19
B-Cell Malignancies

CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.

CNTY-101 is currently being evaluated in the Phase 1 ELiPSE-1 trial (NCT05336409) for relapsed or refractory CD19 positive B-cell lymphomas.

CNTY-102
γδ ιΤ
CD19 + CD22
B-Cell Malignancies

CNTY-102 is an iPSC-derived dual CD19/CD22 targeting γδ iT product candidate for relapsed/refractory lymphoma and other B-cell malignancies. Dual targeting of CNTY-102 is designed to counter antigen escape relapse, which is a major limiting factor for durability of CD19 CAR-T therapies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-102’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-102 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.

CLDE-308
αβ ιΤ
CD19
B-Cell Malignancies

CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for B-cell malignancies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.

CNTY-104
iNK/ιΤ
Multi-specific
AML

CNTY-104 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for acute myeloid leukemia currently being developed in collaboration with Bristol Myers Squibb.

CNTY-106
iNK/ιΤ
Multi-specific
MM

CNTY-106 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for multiple myeloma currently being developed in collaboration with Bristol Myers Squibb.

CNTY-107
γδ ιΤ
Nectin-4
Solid Tumors

CNTY-107 is an iPSC-derived Nectin-4 targeting CAR γδ iT product candidate for solid tumors. CNTY-107 is engineered with Allo-Evasion™ edits and other features to provide cytokine support, enhance tumor cell killing and cell fitness.

Research
ιΤ
Not disclosed
Solid Tumors

An undisclosed iT cell therapy focused research program for solid tumors.

Research
iNK/ιΤ
TBD
Hematologic and Solid Tumors

An undisclosed iNK or iT cell therapy focused research program for hematologic and solid tumors.

Autoimmune Diseases

Hematologic Tumors

Solid Tumors